IDEV Technologies Announces First U.S. Procedure With SUPERA VERITAS(TM) Transhepatic Biliary System

Commercial Launch of Stent Delivery System Planned for Early 2011

WEBSTER, Texas, November 30, 2010 - IDEV Technologies, Incorporated (IDEV), an innovative leader in the
development and commercialization of minimally invasive medical technologies,
today announced the first procedure in the United States utilizing the SUPERA
VERITAS(TM) Transhepatic Biliary System, which was recently cleared to market
by the U.S. Food and Drug Administration.

The SUPERA(R) wire interwoven nitinol stent is currently cleared in the
U.S. for palliative treatment of biliary strictures produced by malignant
neoplasms. Biliary strictures involve a narrowing of the bile duct, the
body's transportation system for fluid that is an essential aid to the
digestion of food. Stents are commonly used to reopen the bile duct and
restore the natural flow of fluids.

Mark Garcia, M.D., FSIR, is Chief of Interventional Radiology at
Christiana Care Health System in Newark, Delaware. He is the first physician
in the U.S. to treat a patient's biliary stricture with the new SUPERA
VERITAS system. "The Supera's high radial strength is uniquely suited for
treating biliary strictures. Because of its characteristics, I've deployed a
number of SUPERA stents over the past year. This new delivery system worked
flawlessly. The driving mechanism was smooth and very responsive. The
post-procedure images revealed optimal stent placement with excellent
cholangiographic results and patency. I'm very pleased with the result."

"We're thrilled to get positive feedback on the initial deployment of the
SUPERA VERITAS system in the U.S.," commented Christopher M. Owens, President
and CEO of IDEV. "Dr. Garcia's experience mirrors that of our customers in
Europe and Canada, where the SUPERA VERITAS system has been in use for the
past year. The stent's radial strength and flexibility combine to produce
extremely high fracture resistance, and may redefine how patients are
treated."

Full commercial launch of the SUPERA VERITAS Transhepatic Biliary System
is planned for the first quarter of 2011.

About IDEV Technologies, Incorporated

IDEV Technologies, Incorporated (IDEV) is an innovator and developer of
next generation medical devices for use in interventional radiology, vascular
surgery and cardiology. IDEV's worldwide headquarters is located in Webster,
Texas and its European headquarters is located in Beuningen, The Netherlands.
Please visit www.idevmd.com.

The SUPERA stent is currently indicated in the U.S. for the palliative
treatment of biliary strictures produced by malignant neoplasms and in Europe
for the treatment of biliary strictures produced by malignant neoplasms and
for peripheral vascular use following failed percutaneous transluminal
angioplasty (PTA).

    Contact: Donna Lucchesi
             Vice President Global Marketing
             IDEV Technologies, Incorporated
             +1-281-525-2000

Donna Lucchesi, Vice President Global Marketing of IDEV Technologies, Incorporated, +1-281-525-2000